Company Description

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.

Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave’s disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Conduit Pharmaceuticals Inc.

Country	United States
Founded	2019
Industry	Biotechnology
Sector	Healthcare
Employees	7
CEO	David Tapolczay

Contact Details

Address: 4995 Murphy Canyon Road, Suite 300 San Diego, California 92123 United States
Phone	760 471 8536
Website	conduitpharma.com

Stock Details

Ticker Symbol	CDT
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001896212
CUSIP Number	20678X106
ISIN Number	US20678X1063
Employer ID	87-3272543
SIC Code	2834

Key Executives

Name	Position
Dr. David Joszef Tapolczay	Chief Executive Officer and Director
James Bligh	Interim Chief Financial Officer and Director
Dr. Joanne M. Holland	Chief Scientific Officer
Bill Begien	Senior Vice President of Investor Relations

Latest SEC Filings

Date	Type	Title
Jan 15, 2025	424B5	Filing
Jan 14, 2025	8-K	Current Report
Dec 20, 2024	8-K	Current Report
Dec 17, 2024	8-K	Current Report
Dec 16, 2024	424B3	Prospectus
Dec 9, 2024	424B3	Prospectus
Dec 6, 2024	DEF 14A	Other definitive proxy statements
Dec 6, 2024	EFFECT	Notice of Effectiveness
Dec 2, 2024	UPLOAD	Filing
Nov 26, 2024	PRE 14A	Other preliminary proxy statements

View All SEC Filings